Switch to:
Nivalis Therapeutics Inc (NAS:NVLS)
EV/EBITDA
-1.93 (As of Today)

EV/EBITDA ratio is calculated as enterprise value divided by its EBITDA. As of today, Nivalis Therapeutics Inc's enterprise value is $56.17 Mil. Nivalis Therapeutics Inc's earnings before depreciation and amortization for the trailing twelve months (TTM) ended in Jun. 2016 was $-29.11 Mil. Therefore, Nivalis Therapeutics Inc's EV/EBITDA ratio for today is -1.93.

NVLS' s EV/EBITDA Range Over the Past 10 Years
Min: -1.93   Max: 1.62
Current: -1.93

-1.93
1.62

During the past 4 years, the highest EV/EBITDA Ratio of Nivalis Therapeutics Inc was 1.62. The lowest was -1.93. And the median was 0.00.

NVLS's EV/EBITDA is ranked lower than
99.99% of the 258 Companies
in the Global Biotechnology industry.

( Industry Median: 19.61 vs. NVLS: -1.93 )

EV/EBITDA (Enterprise value/EBITDA) is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the P/E Ratio to determine the fair market value of a company.

As of today, Nivalis Therapeutics Inc's stock price is $8.38. Nivalis Therapeutics Inc's earnings per share for the trailing twelve months (TTM) ended in Jun. 2016 was $-1.66. Therefore, Nivalis Therapeutics Inc's P/E Ratio for today is .

The "classic" EV/EBITDA ratio is much better in capturing debt and net cash than the P/E Ratio.


Definition

Nivalis Therapeutics Inc's EV/EBITDA for today is calculated as:

EV/EBITDA=Enterprise Value (Today)/Earnings Before Depreciation and Amortization (TTM)
=56.166/-29.109
=-1.93

Nivalis Therapeutics Inc's current Enterprise Value is $56.17 Mil.
Nivalis Therapeutics Inc's Earnings Before Depreciation and Amortization for the trailing twelve months (TTM) ended in Jun. 2016 was -6.085 (Sep. 2015 ) + -6.611 (Dec. 2015 ) + -7.853 (Mar. 2016 ) + -8.56 (Jun. 2016 ) = $-29.11 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

EV/EBITDA (Enterprise value/EBITDA) is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the P/E Ratio to determine the fair market value of a company.

Nivalis Therapeutics Inc's P/E Ratio for today is calculated as:

P/E Ratio=Share Price (Today)/Earnings Per Share (TTM)
=8.38/-1.66
=

Nivalis Therapeutics Inc's share price for today is $8.38.
Nivalis Therapeutics Inc's Earnings Per Share for the trailing twelve months (TTM) ended in Jun. 2016 was -0.39 (Sep. 2015 ) + -0.21 (Dec. 2015 ) + -0.51 (Mar. 2016 ) + -0.55 (Jun. 2016 ) = $-1.66.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Study has found that the companies with the lowest EV/EBITDA outperforms companies measured as cheap by other ratios such as P/E Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Related Terms

Enterprise Value, Earnings Before Depreciation and Amortization, P/E Ratio


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Nivalis Therapeutics Inc Annual Data

Dec12Dec13Dec14Dec15
ev2ebitda 0.000.000.000.000.000.000.000.000.00-1.42

Nivalis Therapeutics Inc Quarterly Data

Mar14Jun14Sep14Dec14Mar15Jun15Sep15Dec15Mar16Jun16
ev2ebitda 0.000.000.000.000.00-6.35-5.49-1.420.600.09
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK